Cencora, Inc.

Cencora, Inc. is one of the three largest pharmaceutical distributors in the United States, operating the backbone logistics infrastructure that moves prescription drugs from manufacturers to the hospitals, retail pharmacies, physician practices, and veterinary clinics where patients receive them, generating $321.3 billion in revenue in fiscal 2025. Alongside McKesson and Cardinal Health, Cencora handles roughly a third of the branded and generic pharmaceutical volume that flows through the U.S. wholesale channel, a position that makes it at once indispensable to the healthcare system and structurally constrained to sub-2% operating margins.

This is a story about an infrastructure business attempting to layer higher-margin growth on top of a low-margin core that faces genuine structural headwinds. Cencora spent the last three years transforming itself — changing its name from AmerisourceBergen, acquiring management services organizations in oncology and retina care, and rationalizing non-core assets including its animal health business. The file turns on a single question: whether the MSO and specialty investments can grow fast enough to lift consolidated returns before customer consolidation, biosimilar bypass, and manufacturer price-reduction mandates erode the economics of the legacy distribution business.

The market's verdict has been volatile. After touching above $375 in February 2026, Cencora shares fell to the $245 range in early May following a second-quarter earnings report that cut revenue guidance on faster-than-expected brand-to-biosimilar conversions and slowing GLP-1 growth. At roughly $263 as of early June 2026, the stock trades at approximately 15 times the midpoint of management's fiscal 2026 adjusted EPS guidance — a multiple that prices in skepticism about the growth algorithm but acknowledges the floor, given the business has never lost money on an operating basis and generates roughly $3 billion a year in free cash flow.